Company Encyclopedia
View More
name
MEI Pharma
MEIP.US
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc.
1.945 T
MEIP.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking348/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-89.74%E
    • Profit Margin0.00%D
    • Gross Margin0.00%E
  • Growth ScoreE
    • Revenue YoY-100.00%E
    • Net Profit YoY-221.06%E
    • Total Assets YoY-70.84%E
    • Net Assets YoY-61.71%E
  • Cash ScoreD
    • Cash Flow Margin0.00%D
    • OCF YoY-100.00%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreA
    • Gearing Ratio5.96%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Lite Strategy, Inc. SEC 10-K Report

    Lite Strategy, Inc. (formerly MEI Pharma, Inc.) has released its 10-K report for the fiscal year ending June 30, 2025, highlighting a strategic pivot to digital assets with a focus on a Litecoin Treasury Strategy. The company reported no revenue and a net loss of $15.9 million. Key changes include a rebranding, leadership shifts, and the closure of a $100 million PIPE financing. Future plans involve digital asset management and potential Litecoin mining, while facing market volatility and regulatory risks.

    TradingView·
    US
    LITS
    -4.29%
    US
    MEIP
    0.00%
    TradingView·
    US
    LITS
    -4.29%
    US
    MEIP
    0.00%

    MEI Pharma Inc. Files Initial Statement of Beneficial Ownership for Alexander Schornstein

    MEI Pharma Inc. has filed an initial statement of beneficial ownership, identifying Alexander Schornstein as the beneficial owner. The full filing is available through the provided link. This news brief was generated by Public Technologies and is for informational purposes only, not to be considered as financial, investment, or legal advice. The original content was published via EDGAR on September 10, 2025.

    Reuters·
    US
    MEIP
    0.00%
    US
    LITS
    -4.29%
    Reuters·
    US
    MEIP
    0.00%
    US
    LITS
    -4.29%

    MEI Pharma Rebrands as Lite Strategy, Adopts New Ticker 'LITS'

    MEI Pharma Inc. has rebranded as Lite Strategy, Inc., reflecting its new focus on digital asset treasury management. The company's NASDAQ ticker symbol will change from MEIP to LITS.

    Reuters·
    US
    MEIP
    0.00%
    US
    LITS
    -4.29%
    Reuters·
    US
    MEIP
    0.00%
    US
    LITS
    -4.29%

    Uncovering the most mysterious investment institution MOZAYYX

    MOZAYYX is a mysterious investment advisory firm in the cryptocurrency sector, with no public information on its founders. It has invested in several projects, including Eightco Holdings, which raised $250 million for Worldcoin, and CleanCore Solutions, which raised $175 million for a DOGE fund. MOZAYYX also participated in a $100 million investment in MEI Pharma, making it the first publicly listed company to use Litecoin as a reserve asset. Additionally, it led a $250 million private placement for BitMine, focusing on Ethereum as a treasury reserve.

    CoinLive·
    US
    MEIP
    0.00%
    US
    OCTO
    0.00%
    US
    ORBS
    -7.32%
    CoinLive·
    US
    MEIP
    0.00%
    US
    OCTO
    0.00%
    US
    ORBS
    -7.32%

    12 Health Care Stocks Moving In Monday's Intraday Session

    In Monday's intraday session, Rapport Therapeutics (RAPP) saw a significant gain of 117.7%, reaching $31.26, with a market cap of $524.1 million. Other notable gainers included Beyond Air (XAIR) up 60.62%, Talphera (TLPH) up 28.36%, and Acrivon Therapeutics (ACRV) up 27.81%. Conversely, CDT Equity (CDT) experienced the largest drop, falling 31.1% to $0.81. Other losers included MEI Pharma (MEIP) down 28.14% and Summit Therapeutics (SMMT) down 24.74%.

    benzinga_article·
    US
    MEIP
    0.00%
    US
    ACRV
    -1.87%
    US
    XAIR
    -3.52%
    benzinga_article·
    US
    MEIP
    0.00%
    US
    ACRV
    -1.87%
    US
    XAIR
    -3.52%
    © 2025 Longbridge｜Disclaimer